QC
SRPT icon

Quent Capital’s Sarepta Therapeutics SRPT Stock Holding History

Quent Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.19K Sell
400
-335
-46% -$6.34K ﹤0.01% 1310
2026
Q1 		$16K Buy
735
+324
+79% +$6.27K ﹤0.01% 1050
2025
Q4 		$8.85K Buy
411
+79
+24% +$1.67K ﹤0.01% 1181
2025
Q3 		$6.4K Buy
+332
New +$5.92K ﹤0.01% 1102
2025
Q2 		– Sell
-16
Closed -$1.02K – 1108
2025
Q1 		$1.02K Hold
16
– – ﹤0.01% 1210
2024
Q4 		$1.95K Hold
16
– – ﹤0.01% 1173
2024
Q3 		$2K Hold
16
– – ﹤0.01% 1225
2024
Q2 		$2.53K Buy
16
+3
+23% +$385 ﹤0.01% 1188
2024
Q1 		$1.68K Buy
13
+11
+550% +$1.35K ﹤0.01% 1248
2023
Q4 		$193 Sell
2
-95
-98% -$9.11K ﹤0.01% 1307
2023
Q3 		$11.8K Sell
97
-17
-15% -$1.92K ﹤0.01% 902
2023
Q2 		$13.1K Hold
114
– – ﹤0.01% 880
2023
Q1 		$15.7K Buy
114
+97
+571% +$12.6K ﹤0.01% 829
2022
Q4 		$2.2K Buy
+17
New +$1.97K ﹤0.01% 1134

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Quent Capital's SRPT Position: Q2 2026 in Review

Quent Capital reduced its Sarepta Therapeutics (SRPT) stake by 46% in Q2 2026, selling an estimated $6.34K and leaving 400 shares worth $7.19K. The position accounts for ﹤0.01% of the portfolio, ranked #1310.

Quent Capital first reported a position in SRPT in Q4 2022 and has held it in 14 quarters since. The position peaked at $16K in Q1 2026. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Quent Capital held 400 shares of Sarepta Therapeutics worth $7.19K as of Q2 2026.
  • Quent Capital sold 335 Sarepta Therapeutics shares in Q2 2026, an estimated $6.34K.
  • Sarepta Therapeutics made up ﹤0.01% of Quent Capital's portfolio in Q2 2026, its #1310 holding.
  • Quent Capital first reported a position in Sarepta Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Quent Capital's Sarepta Therapeutics position peaked at $16K in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.